HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALEBUND-B

22.700

-1.320-5.50%

Volume:295.90K

Turnover:6.89M

Market Cap:7.90B

PE:-7.39

High:24.780

Open:24.060

Low:22.480

Close:24.020

52wk High:46.820

52wk Low:22.480

Shares:348.00M

HK Float Shares:236.00M

Volume Ratio:0.23

T/O Rate:0.13%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-3.071

ROE:--

ROA:-33.01%

PB:4.80

PE(LYR):-7.39

PS:55.10

Loading ...

Overview Company News Filings

Alebund Pharma’s AP301 Capsule NDA Accepted by China’s NMPA for Dialysis-Related Hyperphosphatemia

Bulletin Express

Alebund Pharma Says China NMPA Accepts AP301 Hyperphosphatemia NDA for Review

Alebund Pharmaceuticals (Jiangsu) - Nmpa China Accepts Nda for AP301 Capsules for Hyperphosphatemia in Ckd Dialysis Patients

THOMSON REUTERS

Alebund Pharma Expects H1 Revenue RMB 103 Million-RMB 106 Million, up About 750%-775%

Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million

Bulletin Express

Hong Kong Stock Moves: ALEBUND-B Rises Over 6% After Global Phase IIb Trial Milestone for AP306

Alebund Pharmaceuticals Publishes July 2026 Articles of Association, Confirms RMB348.37 Million Capital and Governance Framework

Bulletin Express

Alebund Pharmaceuticals Amends Bylaws to Update Registered Capital to RMB 348.37 Million

ALEBUND-B (09637) Issued 8.51 Million Shares Following Full Exercise of Over-Allotment Option

Alebund Pharma Nets HK$185 Million From Full Exercise of IPO Over-Allotment Option

MT Newswires Live

Alebund Pharmaceuticals Says no Market Purchases Made for Price Stabilization During IPO Stabilisation Period

Tencent Holdings Boosts Stake in ALEBUND-B with 238,500 Share Purchase

ALEBUND-B: Tencent Holdings Limited Acquires Shares, Long Position Rises to 10.09%

Alebund Pharma adopts electronic dissemination of corporate communications under HKEX paperless regime

Bulletin Express

Alebund Pharmaceuticals Adopts Fully Electronic Dissemination of Corporate Communications

Bulletin Express

Alebund Pharma Doses First Patient in Global Phase 2b Hyperphosphatemia Trial

MT Newswires Live

ALEBUND-B Advances Global Phase IIb Trial for Hyperphosphatemia Treatment with First Patient Dosed

Alebund Pharmaceuticals, R1 Therapeutics Partner on Global Development of AP306 Outside Greater China

Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase Iib Multi-regional Clinical Trial of AP306 for Hyperphosphatemia

THOMSON REUTERS

ALEBUND-B Shares Surge Over 11% in Morning Session Following Major Institutional Buys; AP301 Nears NDA Submission

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/09637/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"09637","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"ALEBUND-B","latestPrice":22.7,"timestamp":1789371628443,"preClose":24.02,"halted":0,"volume":295900,"delay":0,"changeRate":-0.05495420482930892,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"Trading","change":-1.32,"latestTime":"09-14 15:42:19","open":24.06,"high":24.78,"low":22.48,"amount":6890883,"amplitude":0.095754,"askPrice":22.84,"askSize":900,"bidPrice":22.7,"bidSize":900,"shortable":0,"etf":0,"ttmEps":-2.326,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789373400000},"marketStatusCode":2,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":24.02,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"volumeRatio":0.22854,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09637\",,,,,undefined,":{"symbol":"09637","floatShares":236000000,"roa":"-33.01%","roe":"--","lyrEps":-3.071284,"volumeRatio":0.22854,"shares":348000000,"dividePrice":0,"high":24.78,"amplitude":0.095754,"preClose":24.02,"low":22.48,"week52Low":22.48,"pbRate":"4.80","psRate":"55.10","week52High":46.82,"institutionHeld":0,"latestPrice":22.7,"eps":-3.071284,"divideRate":0,"volume":295900,"delay":0,"ttmEps":-2.326,"open":24.06,"prevYearClose":22.6,"prevWeekClose":24.02,"prevMonthClose":31.48,"prevQuarterClose":45.92,"fiveDayClose":26.9,"twentyDayClose":33.74,"sixtyDayClose":22.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09637\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"09637","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09637\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09637\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":3,"updateTime":1787846400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09637\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09637","date":"2026-09-11","current":-9.759243,"percent":0.943396,"low":-18.066068,"twenty":-12.953815,"median":-11.760082,"eighty":-10.889159,"high":-8.42626,"avg":-11.942413,"sd":1.739789,"marketCap":8163250588},"quantilePoints":[{"date":"2026-06-26","current":-8.87585,"twenty":-8.87585,"median":-8.87585,"eighty":-8.87585,"marketCap":7680660420},{"date":"2026-07-03","current":-11.883178,"twenty":-18.03155,"median":-11.883178,"eighty":-9.78101,"marketCap":10290725554},{"date":"2026-07-10","current":-12.164969,"twenty":-13.966639,"median":-11.847257,"eighty":-11.12129,"marketCap":10521825071},{"date":"2026-07-17","current":-10.947234,"twenty":-12.322489,"median":-11.455859,"eighty":-10.783874,"marketCap":9502268378},{"date":"2026-07-24","current":-11.320561,"twenty":-11.939536,"median":-11.377389,"eighty":-10.939493,"marketCap":9828526520},{"date":"2026-07-31","current":-10.642718,"twenty":-11.840073,"median":-11.194259,"eighty":-10.78337,"marketCap":9257574772},{"date":"2026-08-07","current":-12.743391,"twenty":-12.396338,"median":-11.399787,"eighty":-10.889159,"marketCap":11106370909},{"date":"2026-08-14","current":-13.03884,"twenty":-12.987078,"median":-11.462395,"eighty":-10.903987,"marketCap":11378252693},{"date":"2026-08-21","current":-12.870195,"twenty":-13.077865,"median":-11.725167,"eighty":-10.931752,"marketCap":11255905890},{"date":"2026-08-28","current":-12.144658,"twenty":-13.077865,"median":-11.990608,"eighty":-10.959851,"marketCap":10623780741},{"date":"2026-09-04","current":-11.919154,"twenty":-12.988947,"median":-11.883178,"eighty":-10.931752,"marketCap":9787744252},{"date":"2026-09-11","current":-9.927508,"twenty":-12.953815,"median":-11.760082,"eighty":-10.889159,"marketCap":8163250588}],"updateTime":1789371739262},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09637\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1172591515","title":"Alebund Pharma’s AP301 Capsule NDA Accepted by China’s NMPA for Dialysis-Related Hyperphosphatemia","url":"https://stock-news.laohu8.com/highlight/detail?id=1172591515","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172591515?lang=en_us&edition=fundamental","pubTime":"2026-08-07 18:05","pubTimestamp":1786097158,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited announced that the National Medical Products Administration of China (NMPA) has accepted for review the New Drug Application (NDA) for AP301, a novel oral...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657461974","title":"Alebund Pharma Says China NMPA Accepts AP301 Hyperphosphatemia NDA for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2657461974","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657461974?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:25","pubTimestamp":1786094750,"startTime":"0","endTime":"0","summary":"Alebund Pharma says China NMPA accepts AP301 hyperphosphatemia NDA for reviewNMPA accepted Alebund’s China NDA for AP301 capsules to treat hyperphosphatemia in chronic kidney disease patients on maintenance dialysis.Filing backed mainly by RESPOND-1, a China Phase III trial that met primary endpoints, showing non-inferiority to sevelamer carbonate at week 12.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alebund Pharmaceuticals  Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on August 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL1fB9sT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619710","title":"Alebund Pharmaceuticals (Jiangsu) - Nmpa China Accepts Nda for AP301 Capsules for Hyperphosphatemia in Ckd Dialysis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619710?lang=en_us&edition=fundamental","pubTime":"2026-08-07 17:25","pubTimestamp":1786094704,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN4432DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657518686","title":"Alebund Pharma Expects H1 Revenue RMB 103 Million-RMB 106 Million, up About 750%-775%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657518686","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657518686?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:39","pubTimestamp":1786005588,"startTime":"0","endTime":"0","summary":"Alebund Pharma expects H1 revenue RMB 103 million-RMB 106 million, up about 750%-775%Alebund flagged revenue of RMB 103 million–RMB 106 million for the six months ended June 30, 2026, up about 750%–77","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL4z89TP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154239524","title":"Alebund Pharmaceuticals Completes 8.51 Million-Share Over-Allotment, Total Issued Capital Rises to 348.37 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1154239524","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154239524?lang=en_us&edition=fundamental","pubTime":"2026-08-05 16:52","pubTimestamp":1785919927,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited issued and allotted 8.51 million H shares on 29 July 2026 following the full exercise of the over-allotment option disclosed on 24 July 2026. The shares were...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113931304","title":"Hong Kong Stock Moves: ALEBUND-B Rises Over 6% After Global Phase IIb Trial Milestone for AP306","url":"https://stock-news.laohu8.com/highlight/detail?id=1113931304","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113931304?lang=en_us&edition=fundamental","pubTime":"2026-08-03 15:44","pubTimestamp":1785743066,"startTime":"0","endTime":"0","summary":"ALEBUND-B (09637) shares surged more than 6% in Hong Kong trading, reaching HK$29.06 by the time of writing, up 6.68%, with a turnover of HK$4.6856 million.According to a recent update from the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK4588","IBBJ","BK4585","09939","BK1515","KCAI","BK1191","VXUS","159938","PSYK","MDTX","BK1161","BMED","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197845152","title":"Alebund Pharmaceuticals Publishes July 2026 Articles of Association, Confirms RMB348.37 Million Capital and Governance Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1197845152","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197845152?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:24","pubTimestamp":1785331484,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited, which is scheduled to list 56.76 million H shares on the Hong Kong Main Board on 29 June 2026 (CSRC filing date: 24 April 2026), released its updated...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655893917","title":"Alebund Pharmaceuticals Amends Bylaws to Update Registered Capital to RMB 348.37 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655893917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655893917?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:04","pubTimestamp":1785330249,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals amends bylaws to update registered capital to RMB 348.37 millionAlebund Pharmaceuticals (Jiangsu) amended its articles to reflect a larger share capital following full exercise","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL6SD53t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141020089","title":"ALEBUND-B (09637) Issued 8.51 Million Shares Following Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1141020089","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141020089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 17:26","pubTimestamp":1785317175,"startTime":"0","endTime":"0","summary":"On July 29, 2026, ALEBUND-B (09637) issued a corporate announcement.According to the announcement, the company issued and allotted 8.5133 million H-shares on that date. This issuance was a direct...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","09939","159938","BK1515","BK1161","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654955480","title":"Alebund Pharma Nets HK$185 Million From Full Exercise of IPO Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2654955480","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654955480?lang=en_us&edition=fundamental","pubTime":"2026-07-27 10:12","pubTimestamp":1785118356,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals   said the over-allotment option of its Hong Kong initial public offering was fully exercised on Friday, according to a same-day Hong Kong bourse filing.The biopharmaceutical company expects to raise about HK$184.7 million in additional net proceeds.The exercise involved the issue of 8.51 million additional H-shares at HK$22.60 each, representing about 15% of the total offer shares available under the global offering.Dealings in the over-allotment shares are expected to begin on July 29, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KCE","IPOS","09637","FRHC","BK4127","REDS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653071567","title":"Alebund Pharmaceuticals Says no Market Purchases Made for Price Stabilization During IPO Stabilisation Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2653071567","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653071567?lang=en_us&edition=fundamental","pubTime":"2026-07-24 16:32","pubTimestamp":1784881925,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals says no market purchases made for price stabilization during IPO stabilisation periodAlebund Pharmaceuticals (Jiangsu) fully exercised its over-allotment option on July 24, 202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL1Bj1ks:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","BK1191","BK4127","09637","JEF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118027382","title":"Tencent Holdings Boosts Stake in ALEBUND-B with 238,500 Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1118027382","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118027382?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:36","pubTimestamp":1784806597,"startTime":"0","endTime":"0","summary":"Information from the Hong Kong Stock Exchange reveals that on July 17, Tencent Holdings Limited increased its holding in ALEBUND-B (09637) by 238,500 shares.The transaction was executed at an average...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","EDZ","EWH","BK1515","BK1161","BK4585","IEMG","09939","09637","BK4581","159938","BK4550","BK4504","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167044050","title":"ALEBUND-B: Tencent Holdings Limited Acquires Shares, Long Position Rises to 10.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167044050","media":"HK Disclosure","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167044050?lang=en_us&edition=fundamental","pubTime":"2026-07-23 17:12","pubTimestamp":1784797975,"startTime":"0","endTime":"0","summary":"Tencent Holdings Limited bought 238,500 shares of ALEBUND-B stock at an average of HKD 27.9667 per share on July 17, 2026, involving about HKD 6.67 million.Prior to the acquisition, Tencent Holdings...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185122732","title":"Alebund Pharma adopts electronic dissemination of corporate communications under HKEX paperless regime","url":"https://stock-news.laohu8.com/highlight/detail?id=1185122732","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185122732?lang=en_us&edition=fundamental","pubTime":"2026-07-22 17:42","pubTimestamp":1784713347,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited announced that, in line with Rule 2.07A of the Hong Kong Stock Exchange’s paperless listing regime effective 31 December 2023, all future corporate...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155137463","title":"Alebund Pharmaceuticals Adopts Fully Electronic Dissemination of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1155137463","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155137463?lang=en_us&edition=fundamental","pubTime":"2026-07-22 17:21","pubTimestamp":1784712104,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (Jiangsu) Limited (“Alebund”) announced that, in line with Rule 2.07A of the Hong Kong Stock Exchange’s paperless listing regime effective 31 December 2023, the company will...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653378085","title":"Alebund Pharma Doses First Patient in Global Phase 2b Hyperphosphatemia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653378085","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653378085?lang=en_us&edition=fundamental","pubTime":"2026-07-22 10:32","pubTimestamp":1784687579,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals (HKG:9637) said that the first participant has been randomized and dosed in a global phase 2b clinical trial evaluating AP306 for hyperphosphatemia in patients receiving mainte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188002342","title":"ALEBUND-B Advances Global Phase IIb Trial for Hyperphosphatemia Treatment with First Patient Dosed","url":"https://stock-news.laohu8.com/highlight/detail?id=1188002342","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188002342?lang=en_us&edition=fundamental","pubTime":"2026-07-21 20:03","pubTimestamp":1784635393,"startTime":"0","endTime":"0","summary":"Global Phase IIb multi-regional clinical trial for AP306, targeting hyperphosphatemia in patients on maintenance hemodialysis, has achieved a significant milestone with the first patient randomized...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159938","09939","BK1161","MDTX","IBBJ","09637","PSYK","BK1574","BK1191","BK1515","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653716972","title":"Alebund Pharmaceuticals, R1 Therapeutics Partner on Global Development of AP306 Outside Greater China","url":"https://stock-news.laohu8.com/highlight/detail?id=2653716972","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653716972?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:01","pubTimestamp":1784631708,"startTime":"0","endTime":"0","summary":"Alebund Pharmaceuticals, R1 Therapeutics partner on global development of AP306 outside Greater ChinaAlebund Pharmaceuticals granted R1 Therapeutics an exclusive license for AP306 outside mainland Chi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL6LWnHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271584","title":"Alebund Pharmaceuticals Announces First Participant Randomized and Dosed in Global Phase Iib Multi-regional Clinical Trial of AP306 for Hyperphosphatemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653271584?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:00","pubTimestamp":1784631602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nTUA2BSV3K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182922213","title":"ALEBUND-B Shares Surge Over 11% in Morning Session Following Major Institutional Buys; AP301 Nears NDA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=1182922213","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182922213?lang=en_us&edition=fundamental","pubTime":"2026-07-15 10:54","pubTimestamp":1784084068,"startTime":"0","endTime":"0","summary":"Shares of ALEBUND-B (ASX: 09637) surged more than 11% during the morning trading session. At the time of writing, the stock was up 9.62% to HK$30.54, with a turnover of HK$4.20 million. On June 29th,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK1515","BK1574","BK4585","BK1191","BK4588","159938","KCAI","GIC","VXUS","BK1161","09939","09637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":67,"code":"91000000","status":"200"}]}}